| EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 55 (2), 245-264, 2011 | 2527 | 2011 |
| EASL recommendations on treatment of hepatitis C 2018 European Association for The Study of The Liver Journal of hepatology 69 (2), 461-511, 2018 | 2015* | 2018 |
| Genomewide association study of severe Covid-19 with respiratory failure Severe Covid-19 GWAS Group New England Journal of Medicine 383 (16), 1522-1534, 2020 | 1995 | 2020 |
| EASL recommendations on treatment of hepatitis C: final update of the series☆ JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ... Journal of hepatology 73 (5), 1170-1218, 2020 | 827 | 2020 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 804 | 2021 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 525 | 2019 |
| A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis R D'Ambrosio, A Aghemo, MG Rumi, G Ronchi, MF Donato, V Paradis, ... Hepatology 56 (2), 532-543, 2012 | 501 | 2012 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 439 | 2022 |
| COVID-19 and liver disease J Sun, A Aghemo, A Forner, L Valenti Liver international 40 (6), 1278-1281, 2020 | 422 | 2020 |
| High rates of 30-day mortality in patients with cirrhosis and COVID-19 M Iavarone, R D'Ambrosio, A Soria, M Triolo, N Pugliese, P Del Poggio, ... Journal of hepatology 73 (5), 1063-1071, 2020 | 402 | 2020 |
| Patatin‐like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C L Valenti, MG Rumi, E Galmozzi, A Aghemo, B Del Menico, S De Nicola, ... Hepatology 53 (3), 791-799, 2011 | 302 | 2011 |
| Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C MG Rumi, A Aghemo, GM Prati, R D'Ambrosio, MF Donato, R Soffredini, ... Gastroenterology 138 (1), 108-115, 2010 | 288 | 2010 |
| Impact of COVID-19 on global HCV elimination efforts S Blach, LA Kondili, A Aghemo, Z Cai, E Dugan, C Estes, I Gamkrelidze, ... Journal of hepatology 74 (1), 31-36, 2021 | 281 | 2021 |
| MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals B Donati, P Dongiovanni, S Romeo, M Meroni, M McCain, L Miele, S Petta, ... Scientific reports 7 (1), 4492, 2017 | 269 | 2017 |
| EASL recommendations on treatment of hepatitis C 2014 European Association for The Study of The Liver Journal of Hepatology 61 (2), 373-395, 2014 | 247 | 2014 |
| Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy M Cecconi, D Piovani, E Brunetta, A Aghemo, M Greco, M Ciccarelli, ... Journal of clinical medicine 9 (5), 1548, 2020 | 229 | 2020 |
| Recommendations for the management of hepatitis C virus infection among people who inject drugs J Grebely, G Robaeys, P Bruggmann, A Aghemo, M Backmund, ... International Journal of Drug Policy 26 (10), 1028-1038, 2015 | 213 | 2015 |
| Treatment with ledipasvir–sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial M Colombo, A Aghemo, H Liu, J Zhang, H Dvory-Sobol, R Hyland, C Yun, ... Annals of internal medicine 166 (2), 109-117, 2017 | 210 | 2017 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 201 | 2022 |
| The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response R D’Ambrosio, A Aghemo, M Fraquelli, MG Rumi, MF Donato, V Paradis, ... Journal of hepatology 59 (2), 251-256, 2013 | 190 | 2013 |
